Travere Therapeutics (TVTX) Net Income towards Common Stockholders (2011 - 2026)
Travere Therapeutics (TVTX) reported Net Income towards Common Stockholders of -$500000.0 for Q1 2026, down 102.02% quarter-over-quarter from $24.7 million in Q4 2025.
Travere Therapeutics (TVTX) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Travere Therapeutics has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$500000.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders changed N/A year-over-year to -$500000.0; the trailing twelve-month figure through Mar 2026 stood at $24.2 million (up 3082.14% YoY), and the FY2025 full-year result was $24.7 million, up 2801.09% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$500000.0, down from $24.7 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $240.0 million in Q3 2023, with the low at -$1.6 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged $24.4 million across 5 years, with a median of $8.0 million in 2022.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 107.96% — and 2025, when it soared 617775.0%.
- Travere Therapeutics' Net Income towards Common Stockholders stood at $19.8 million in 2022, then plunged by 107.96% to -$1.6 million in 2023, then surged by 100.25% to $4000.0 in 2024, then soared by 617775.0% to $24.7 million in 2025, then tumbled by 102.02% to -$500000.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$500000.0 (Q1 2026), $24.7 million (Q4 2025), and $4000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -500,000.00 |
| Dec 31, 2025 | 24.72 Mn |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | -59,000.00 |
| Jun 30, 2024 | -757,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | 239.98 Mn |
| Jun 30, 2023 | 16.30 Mn |
| Mar 31, 2023 | 10.23 Mn |
| Dec 31, 2022 | 19.81 Mn |
| Sep 30, 2022 | 14.41 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 5.78 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.01 Mn |
| Mar 31, 2021 | -53.85 Mn |
| Dec 31, 2020 | -121.62 Mn |
| Sep 30, 2020 | -22.55 Mn |